177 related articles for article (PubMed ID: 38579724)
1. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
Spitzer A; Gritsch S; Nomura M; Jucht A; Fortin J; Raviram R; Weisman HR; Gonzalez Castro LN; Druck N; Chanoch-Myers R; Lee JJY; Mylvaganam R; Lee Servis R; Fung JM; Lee CK; Nagashima H; Miller JJ; Arrillaga-Romany I; Louis DN; Wakimoto H; Pisano W; Wen PY; Mak TW; Sanson M; Touat M; Landau DA; Ligon KL; Cahill DP; Suvà ML; Tirosh I
Cancer Cell; 2024 May; 42(5):904-914.e9. PubMed ID: 38579724
[TBL] [Abstract][Full Text] [Related]
2. Shifting the landscape: The role of IDH inhibitors in glioma cell fate.
Giacobetti SA; Fine HA
Cancer Cell; 2024 May; 42(5):741-743. PubMed ID: 38579726
[TBL] [Abstract][Full Text] [Related]
3. A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
Silvani A; Franceschi E
Tumori; 2024 Jun; 110(3):160-161. PubMed ID: 38166539
[No Abstract] [Full Text] [Related]
4. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
5. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
[TBL] [Abstract][Full Text] [Related]
6. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
7. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
8. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.
Ferguson SD; Zhou S; Huse JT; de Groot JF; Xiu J; Subramaniam DS; Mehta S; Gatalica Z; Swensen J; Sanai N; Spetzler D; Heimberger AB
J Neuropathol Exp Neurol; 2018 Jun; 77(6):437-442. PubMed ID: 29718398
[TBL] [Abstract][Full Text] [Related]
9. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
Venteicher AS; Tirosh I; Hebert C; Yizhak K; Neftel C; Filbin MG; Hovestadt V; Escalante LE; Shaw ML; Rodman C; Gillespie SM; Dionne D; Luo CC; Ravichandran H; Mylvaganam R; Mount C; Onozato ML; Nahed BV; Wakimoto H; Curry WT; Iafrate AJ; Rivera MN; Frosch MP; Golub TR; Brastianos PK; Getz G; Patel AP; Monje M; Cahill DP; Rozenblatt-Rosen O; Louis DN; Bernstein BE; Regev A; Suvà ML
Science; 2017 Mar; 355(6332):. PubMed ID: 28360267
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
[No Abstract] [Full Text] [Related]
11. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
12. Oligosarcomas, IDH-mutant are distinct and aggressive.
Suwala AK; Felix M; Friedel D; Stichel D; Schrimpf D; Hinz F; Hewer E; Schweizer L; Dohmen H; Pohl U; Staszewski O; Korshunov A; Stein M; Wongsurawat T; Cheunsuacchon P; Sathornsumetee S; Koelsche C; Turner C; Le Rhun E; Mühlebner A; Schucht P; Özduman K; Ono T; Shimizu H; Prinz M; Acker T; Herold-Mende C; Kessler T; Wick W; Capper D; Wesseling P; Sahm F; von Deimling A; Hartmann C; Reuss DE
Acta Neuropathol; 2022 Feb; 143(2):263-281. PubMed ID: 34967922
[TBL] [Abstract][Full Text] [Related]
13. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
14. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas.
Blanco-Carmona E; Narayanan A; Hernandez I; Nieto JC; Elosua-Bayes M; Sun X; Schmidt C; Pamir N; Özduman K; Herold-Mende C; Pagani F; Cominelli M; Taranda J; Wick W; von Deimling A; Poliani PL; Rehli M; Schlesner M; Heyn H; Turcan Ş
Cell Rep Med; 2023 Nov; 4(11):101249. PubMed ID: 37883975
[TBL] [Abstract][Full Text] [Related]
15. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
16. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH
Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567
[TBL] [Abstract][Full Text] [Related]
17. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
[TBL] [Abstract][Full Text] [Related]
18. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
19. Stalled oligodendrocyte differentiation in IDH-mutant gliomas.
Wei Y; Li G; Feng J; Wu F; Zhao Z; Bao Z; Zhang W; Su X; Li J; Qi X; Duan Z; Zhang Y; Vega SF; Jakola AS; Sun Y; Carén H; Jiang T; Fan X
Genome Med; 2023 Apr; 15(1):24. PubMed ID: 37055795
[TBL] [Abstract][Full Text] [Related]
20. Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report.
Agopyan-Miu AHCW; Banu MA; Miller ML; Troy C; Hargus G; Canoll P; Wang TJC; Feldstein N; Haggiagi A; McKhann GM
Acta Neuropathol Commun; 2021 Sep; 9(1):160. PubMed ID: 34587990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]